News

TipRanks on MSN2d
Alnylam price target raised to $328 from $325 at BofA
BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in smid-cap ...
HME News8d
Soleo Health secures Qfitlia
Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...
EconoTimes10d
John Calabrese
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
EconoTimes10d
Cailbhe Doherty
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
Managed Healthcare Executive11d
FDA Approves First Prophylactic Therapy for Hemophilia A or B With or Without Inhibitors
Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...
Hemophilia News Today11d
Gene therapy BBM-H901 approved for hemophilia B in China
The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...
Nasdaq18d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
Fitusiran, which will be marketed by the name of Qfitlia, becomes the first therapy approved in the United States for treating hemophilia A or B with or without inhibitors. The approval is based ...
Pharmaceutical Technology18d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug designation.
clinicaladvisor.com19d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...
Medical Xpress20d
FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
Get Instant Summarized Text (Gist) The FDA has approved Qfitlia (fitusiran) for reducing bleeding episodes in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia ...
Too Old to Operate20d
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
WEDNESDAY, April 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
U.S. News & World Report20d
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia By Lori Solomon HealthDay Reporter WEDNESDAY, April 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...